Capricor Prepares To Launch Deramiocel Alone While Its Distributor Dispute Heads To Arbitration
The company cut about 10% of its workforce and slowed other programs as it prepares for a launch contingent on FDA approval.
Capricor Therapeutics, which develops cell-based treatments and therapies using particles released by cells called exosomes, is preparing to launch deramiocel without NS Pharma’s participation, Chief Executive Officer Linda Marbán said on the company’s earnings call Tuesday. The investigational Duchenne muscular dystrophy treatment still needs FDA approval, and arbitration could shape the distributor’s eventual role.
Launch Preparations Without NS Pharma
Capricor is building distribution, patient support, insurance access, medical affairs and physician education capabilities independently while pursuing a contractual dispute with Nippon Shinyaku and NS Pharma over deramiocel’s distribution agreement. Discussions with insurers have begun.
Asked by an H.C. Wainwright analyst about finding a replacement, Marbán said: "We're not looking, obviously, for another partner." She said Capricor intends to commercialize the treatment itself if it achieves separation from NS Pharma.
An analyst from Ladenburg Thalmann asked whether some launch responsibilities might ultimately return to NS Pharma. Marbán said the arbitration panel could direct future arrangements, but defended proceeding independently: "There's nothing better than being prepared, right?"
Capricor withdrew its request for a preliminary injunction without prejudice and expects the arbitration hearing to begin in mid-2027. Responding to a Cantor Fitzgerald analyst, Marbán said she does not expect arbitration to impede delivery to patients if the FDA approves deramiocel.
Higher Spending, Fewer Employees
Capricor reduced its workforce by approximately 10% in the third quarter and slowed pipeline work unrelated to deramiocel. Marbán said those decisions conserve resources for the treatment while its regulatory review continues.
Chief Financial Officer A.J. Bergmann said third-quarter operating expenses reached approximately $44.7 million, compared with $26.3 million a year earlier. He attributed the increase primarily to preparations for commercialization and expanded manufacturing.
The quarterly net loss widened to approximately $42.7 million, or $0.73 per share, from $24.6 million, or $0.54 per share. For the first nine months, the loss was $117.3 million versus $74.9 million in the corresponding 2025 period. Neither third quarter generated recognized revenue.
Cash, cash equivalents, restricted cash and marketable securities totaled approximately $198.5 million as of September 30, 2026. Bergmann said existing cash, cash equivalents and marketable securities should fund operations for at least the next 12 months under the current operating plan. Capricor sold no shares through its at-the-market share-sale program this year.
Capricor has no products approved for commercial sale. Its lead candidate targets Duchenne’s heart and skeletal-muscle complications, primarily in adolescents and young adults; the company also operates deramiocel manufacturing facilities in San Diego and Los Angeles.
An Upper-Limb Decision, Then Capacity
The FDA rejected the application in July 2025, citing insufficient evidence of effectiveness for cardiomyopathy. An advisory committee voted 9–3 against evidence supporting effectiveness for that heart condition at its July meeting.
Capricor’s August amendment proposed an indication for upper-limb impairment in patients older than nine. Marbán said the amendment included two-year extension results and combined efficacy analyses from its placebo-controlled trials; all requested information has been submitted, and review remains ongoing.
Marbán said the late-stage trial showed a 1.1-point difference versus placebo on a measure of shoulder, arm and hand function, with a p-value of 0.029. She described the difference as clinically meaningful. The extension findings are descriptive, she cautioned, rather than another randomized comparison.
San Diego’s operational first-floor manufacturing space can supply 250 patients annually, or around 1,000 doses. Patients typically receive treatment quarterly. Validation of the second-floor expansion is targeted for the first half of 2027; at full capacity, management expects the facility to serve 2,000 to 2,500 patients annually, or up to 10,000 doses.
Capricor has tentatively arranged additional San Diego space should demand require it. Marbán said the company has also begun regulatory engagement in Europe and Japan, while further development for younger boys and Becker muscular dystrophy will be informed by the U.S. review.
The FDA’s target decision date is November 22, 2026. Capricor’s independent launch preparations remain contingent on that approval.
Sources
- FDA's rare disease framework faces its first real test in Capricor’s DMD drug - BioSpace — biospace.com
- CAPR Stock Rises After Deramiocel Cardiac Data Wins American Heart Association Award Ahead Of FDA Decision — Yahoo Finance
- Capricor’s HOPE-3 Phase 3 Cardiac Results for Deramiocel Win American Heart Association Outstanding Research Award in Pediatric Cardiology — Yahoo Finance
- Capricor Therapeutics Reports Third Quarter 2026 Financial — globenewswire.com
- Capricor’s HOPE-3 Phase 3 Cardiac Results for Deramiocel — globenewswire.com